Body found in search for missing dad in reservoir
A body has been found in a reservoir during the search for a man after a boat capsized.
It is believed to be the man who fell into the water with his son at Draycote Water, near Rugby, on Thursday afternoon.
The man's teenage son was rescued by two members of the public and was not injured.
Warwickshire Police said the death was not being treated as suspicious.
An "intensive" search operation took place at the 240-hectare (600-acre) reservoir on Thursday, with specialist search tactics and technology used, said the force.
An update on the search was put out shortly before 23:45 BST on Friday.
Chief Inspector Angus Eagles said: "Our thoughts are very much with the man's family at this incredibly difficult time and I would ask that their privacy continues to be respected.
"I don't underestimate the impact this tragic incident and the large-scale search operation will have had on local people and businesses.
"Thank you all for your patience and understanding while our officers worked tirelessly to find the man."
Chief Insp Eagles also thanked Warwickshire Fire and Rescue, Warwickshire Search and Rescue, West Mercia Search and Rescue, Avon Fire and Rescue Service, West Mercia Police and Severn Trent.
He said they had all played an "integral role" in supporting the extensive search efforts.
A spokesperson for Draycote Water said it would remain shut on Saturday, having been closed since the incident.
This includes the sailing club, fishing club and restaurant.
Watersports such as sailing and windsurfing are popular at the site, and it also attracts anglers.
Follow BBC Coventry & Warwickshire on BBC Sounds, Facebook, X and Instagram.
Dad missing after capsizing on reservoir with son
Man missing after falling from boat on reservoir
Warwickshire Police
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
35 minutes ago
- Medscape
Tezepelumab Curbs Oral Corticosteroid Use in Severe Asthma
The addition of tezepelumab to standard treatment allowed half the adults with severe asthma to discontinue their use of oral corticosteroids (OCS) after 1 year, according to new data from nearly 300 individuals. Tezepelumab, a human monoclonal antibody, has been associated with reduction in the use of OCS in patients with OCS-dependent asthma, David J. Jackson, MD, professor and clinical director, Guy's Severe Asthma Centre at Guy's Hospital King's College London, London, England, and colleagues wrote in an abstract presented at American Thoracic Society (ATS) 2025 International Conference. Many patients with severe asthma take OCS, but previous research has shown associations between extended OCS use and increased risk for a range of side effects including osteoporosis and fractures, hypertension, and infections, and more strategies are needed to help these patients reduce OCS use, the researchers noted. 'We know prolonged oral corticosteroid use leads to adverse effects, including bone, cardiovascular, metabolic, gastrointestinal and psychiatric disorders, and adrenal insufficiency,' Jackson said in an interview. 'The WAYFINDER trial is a multicenter, open-label, single-arm trial evaluating the efficacy and safety of tezepelumab compared to placebo in severe asthma patients who require maintenance use of OCS alongside their standard treatment,' he said. A previous phase 3 OCS-sparing study known as SOURCE did not meet its primary endpoint, but patients with baseline blood eosinophil counts ≥ 150 cels/μL who received tezepelumab achieved a reduction in daily maintenance OCS (mOCS) dose compared with placebo patients, the researchers wrote in their abstract. 'The WAYFINDER trial was designed to accelerate data collection and specifically address the complexities in the SOURCE trial design that may have contributed to the result of the primary endpoint,' Jackson told Medscape Medical News . The WAYFINDER trial enrolled 298 adults with severe asthma who had received OCS for at least 3 months before starting the study. All participants received 210 mg of subcutaneous tezepelumab every 4 weeks for up to 52 weeks after a 4-week induction period. The co-primary endpoints were the proportion of patients who reduced their daily mOCS to 5 mg/d or less or discontinued OCS without loss of asthma control. A total of 273 patients completed the study; the mean baseline mOCS was 10.8 mg/d, and patients were assessed at 28 weeks and 52 weeks. Overall, 88.9% and 89.9% of patients reduced their mOCS to 5 mg/d or less by week 28 and week 52, respectively, while 32.2% and 50.3% discontinued OCS at these time periods, respectively. In a post hoc analysis, 82.2% of patients whose reason for systemic corticosteroids was related to adrenal insufficiency achieved an mOCS dose of 5 mg/d or less without loss of asthma control at week 52. The study was limited by the open-label design, but the safety profile was consistent with previous studies of tezepelumab, researchers said. A 2023 meta-analysis of safety data on tezepelumab for uncontrolled asthma showed that the most common adverse events were nasopharyngitis, headache, and bronchitis, and most AEs occurred within a month of starting tezepelumab. Rates of serious adverse events were lower in patients receiving tezepelumab than those receiving placebo in a pooled analysis. The standout findings from the study are the clinically meaningful reductions in maintenance OCS use or complete discontinuation achieved with tezepelumab among a broad severe asthma patient population, Jackson told Medscape Medical News . In addition, two thirds of participants remained exacerbation-free despite OCS dose reductions, and the OCS-sparing effect of tezepelumab was observed across pre-specified patient subgroups, including those defined by baseline blood eosinophil counts (BEC), fractional exhaled nitric oxide (FeNO) level and allergy status, Jackson said. 'These findings reinforce tezepelumab's efficacy in severe asthma as the first and only biologic targeting thymic stromal lymphopoietin (TSLP) with demonstrated efficacy for severe asthma patients across phenotypes and irrespective of biomarker levels including BEC, allergic status, and FeNO,' he said. Improving Short-Term Health and Long-Term Wellness 'For people living with severe asthma, achieving stable control and reducing or eliminating reliance on oral corticosteroids is a critical goal, not only for respiratory health but also for long-term well-being,' Jackson told Medscape Medical News . 'By showing the benefit of targeting TSLP at the top of the inflammatory cascade and controlling asthma effectively with tezepelumab, we may be able to reduce these risks from OCS and significantly improve control for patients living with severe asthma,' Jackson said. 'We look forward to sharing a manuscript in the future for the phase 3b WAYFINDER study,' he added. Support for Steroid-Sparing The current study highlights an important population: Patients with asthma who are dependent on OCS, said Sucharita Kher, MD, pulmonologist and vice chair of clinical operations and quality for the Department of Medicine at Tufts Medical Center, in an interview. The endpoint tapering OCS without loss of asthma control is clinically meaningful because of the known side effects of OCS, said Kher, who was not involved in the study. The results were not unexpected, but more details on whether patients with eosinophils below 150 cells/µL also benefitted from tezepelumab would be helpful, Kher noted. The data are exciting because they suggest another option for patients with OCS dependent asthma, said Kher. 'The data also guide clinicians to adopt a strategy to wean patients off OCS when on tezepelumab with the goal of reducing OCS exposure and hence, side effects of prolonged OCS use,' she said. 'We know that OCS have side effects and negative consequences on factors including bone health, blood pressure, and blood sugar control and infection risk,' she added. Potential barriers to expanding the use of tezepelumab for reducing OCS in asthma patients exist at the patient and healthcare systems levels, Kher told Medscape Medical News . Patient-level barriers include cost sharing, worry/hesitancy about injections, lack of specialty access, and patient health literacy, she said. In addition, healthcare system barriers include a lack of knowledge on the part of primary care providers, and even some specialty physicians, of the benefits of biologics for severe asthma, said Kher. Other potential challenges include limited infrastructure in clinician offices, such as trained personnel and staff to navigate prior auth/insurance mandates, pre-authorization barriers, and denials based on tiers by insurance companies, she noted. 'Overcoming the barriers requires a multipronged approach, improving awareness and education for healthcare professionals, improve access to specialty care for patients, and advocacy to reduce the processes for insurance approvals,' Kher said.
Yahoo
38 minutes ago
- Yahoo
Liverpool wonderkid is a surprise candidate to REPLACE Luis Diaz
However, at the end of the day, Liverpool will want to bring in someone who can at least provide cover. Maybe not the same quality as Diaz but someone who has the same potential. And for that purpose Liverpool don't have to tap into the market. They can just promote one of the biggest talents in the academy right now. Advertisement We are of course talking about Rio Ngumoha. If Diaz leaves, he must absolutely be a surprise candidate to replace him. Ngumoha is a generational talent. There's a reason why Liverpool went all out to sign him and there's a reason why despite barely being 16-years-old, he's been regularly training with the club's first team all season, and catching the eye in training too. Ngumoha averages 13 dribblers per 90 minutes for Liverpool's academy sides this season. His one vs one ability puts him up there alongside some of the best prospects in the world. He showed against Accrington he can make an impact even against senior players. He's proving that in training sessions week, week out as well. Advertisement The one thing that has been missing a little bit is his end-product. But Ngumoha is improving that as well. He scored a brace in the U21s final game of the Premier League 2 season against Aston Villa. Recently, he provided an assist for England's U17 side in a crucial game against Italy at the U17 Euros and he scored twice and registered an assist against Northern Ireland in the final qualifying game in the lead-up to the tournament. Chelsea thought Ngumoha was good enough to play with the first team at 15-years-old. That's when he was first invited to participate in first team training sessions. He'll be 17-years-old by the start of the 2025/26 season and it already feels like he's ready to make the step-up. Sometimes you have to throw players in at the deep end, especially players as exciting as Ngumoha. If Diaz leaves, it will be a huge opportunity for the young man and Liverpool will absolutely consider Ngumoha as an option to fill the Colombian's void.
Bloomberg
39 minutes ago
- Bloomberg
UK House Prices Post Surprise Increase in May, Nationwide Says
UK house prices unexpectedly rose in May, in a sign that demand for housing remains resilient following the expiry of a tax break for buyers, according to one of Britain's largest mortgage lenders.
